These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 32771558)

  • 1. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 4. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
    Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 8. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
    Hunter BD; Jacobson CA
    J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
    Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
    Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
    Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
    J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.